Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis

Pharmacopsychiatry

Volumn 43, Issue 7, 2010, Pages 281-

  Van Nimwegen Campailla, L ^a,b   Van Beveren, N ^b   Laan, W ^c   Van Den Brink, W ^a,d   Linszen, D ^a   De Haan, L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^d AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; OLANZAPINE; RISPERIDONE;

DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETTER; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SEDATION; SELF REPORT; SIDE EFFECT; SUBJECTIVE WELL BEING UNDER NEUROLEPTICS SCALE; WEIGHT GAIN;

AFFECTIVE SYMPTOMS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; MARIJUANA SMOKING; MEDICATION ADHERENCE; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 78049434577     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1263172     Document Type: Letter

References (2)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 1209-1223
2. Van Nimwegen L, de Haan L, van Beveren JM, et al. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double blind comparison. Can J Psychiatry 2008 53 400-405